At the same time, the decision focused on the accelerated approval process by the Food and Drug Administration and highlighted the strength of the CMS – so that it could have an impact on how quickly other new medicines hit the market. “With this decision, the CMS simply does not say it does not trust Alzheimer’s treatments that have been approved by the FDA through accelerated approval. “It also...
Narrow coverage of Aduhelm has sparked debate about the viability of future treatments
N